Goldman Sachs downgraded Luye Pharma to Sell from Neutral with a price target of HK$3.73, up from HK$3.68. The firm sees modest product sales growth in the coming years and views earnings improvement from potential debt pay-down as reflected in the share price, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>